Novacyt Akcija

Novacyt EBITDA

Vrijednost EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Novacyt (ALNOV.PA) na dan 12. авг 2026. je -7,49 М GBP. Prethodne godine, EBITDA (Заработак пре камата, пореза, амортизације и отписивања) je bio -10,38 М GBP — promjena od -27,85% (viši).

EBITDA

-7,49 МGBP

YoY

-27,85%

Zadnja ažuriranja:

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Novacyt je 2026 -7,49 М GBP. EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Novacyt je bio 2025 -10,38 М GBP. Pad je time -27,85% viši u odnosu na prethodnu godinu.
Access this data via the Eulerpool API

Novacyt Анализа акција

Šta radi Novacyt? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji Novacyt

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) kompanije Novacyt iznosi -7,49 М GBP u 2026. godini.

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Novacyt se promijenio sa -10,38 М GBP na -7,49 М GBP, što predstavlja promjenu od -27,85%. Vrijednost je viši nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj EBITDA (Заработак пре камата, пореза, амортизације и отписивања) Novacyt od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

EBITDA мери оперативну перформансу пре утицаја финансијске структуре, окружења пореза и не-готовинских отписивања.

EBITDA = EBIT + Амортизација и отписивање

EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s GBP je ključan faktor za investitore. Promene u ovoj metrici mogu signalizirati poboljšane ili pogoršane fundamentalne faktore, direktno utiču na cenu akcije. Na Eulopoolu, možete pratiti EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s Novacyt istorijski i u realnom vremenu.

Access this data via the Eulerpool API

Извештај о добити и губитку — Novacyt

Sve ključne metrike — Novacyt

Раст